Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 16c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.34), $0.16 better than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c